Roy Elias

1.0k total citations
40 papers, 411 citations indexed

About

Roy Elias is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Roy Elias has authored 40 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 18 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Roy Elias's work include Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (10 papers). Roy Elias is often cited by papers focused on Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (10 papers). Roy Elias collaborates with scholars based in United States, Austria and Russia. Roy Elias's co-authors include James Brugarolas, Hans J. Hammers, Alana Christie, Payal Kapur, Nirmish Singla, Qing Zhang, Raquibul Hannan, Mark G. Alexandrow, Victoria Bryant and Susan McCarthy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular Cell.

In The Last Decade

Roy Elias

38 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roy Elias United States	11	191	165	141	62	56	40	411
Dongweon Song United States	9	157 0.8×	219 1.3×	79 0.6×	91 1.5×	47 0.8×	11	414
Flora Luo United States	7	100 0.5×	205 1.2×	103 0.7×	47 0.8×	26 0.5×	9	390
Adekemi Taylor United States	4	142 0.7×	338 2.0×	100 0.7×	73 1.2×	24 0.4×	17	482
James Christensen United States	4	137 0.7×	245 1.5×	103 0.7×	65 1.0×	28 0.5×	8	453
Caterina Aversa Italy	12	285 1.5×	210 1.3×	222 1.6×	108 1.7×	62 1.1×	32	553
Arpita Desai United States	10	165 0.9×	229 1.4×	185 1.3×	116 1.9×	31 0.6×	38	451
Anna Elisabetta Brunetti Italy	10	175 0.9×	138 0.8×	45 0.3×	60 1.0×	31 0.6×	18	336
Lany Ruslim United States	6	155 0.8×	308 1.9×	86 0.6×	39 0.6×	27 0.5×	6	514
Candice McCoy United States	11	233 1.2×	286 1.7×	171 1.2×	52 0.8×	106 1.9×	27	501
Davide Bosso Italy	12	132 0.7×	133 0.8×	167 1.2×	70 1.1×	41 0.7×	18	366

Countries citing papers authored by Roy Elias

Since Specialization

Citations

This map shows the geographic impact of Roy Elias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Elias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Elias more than expected).

Fields of papers citing papers by Roy Elias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Elias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Elias. The network helps show where Roy Elias may publish in the future.

Co-authorship network of co-authors of Roy Elias

This figure shows the co-authorship network connecting the top 25 collaborators of Roy Elias. A scholar is included among the top collaborators of Roy Elias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy Elias. Roy Elias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elias, Roy, Thomas R. Nirschl, Michael E. Rezaee, et al.. (2025). Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity. Cancer Research Communications. 5(5). 743–755. 1 indexed citations

Ged, Yasser, Luis Contreras, Roy Elias, et al.. (2025). Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma. Journal of Immunotherapy. 48(3). 113–117. 1 indexed citations

Pallauf, Maximilian, Michael E. Rezaee, Roy Elias, et al.. (2025). Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance. British Journal of Urology. 135(5). 860–868. 1 indexed citations

Vlachou, Evangelia, Burles A. Johnson, Roy Elias, et al.. (2024). Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.. Journal of Clinical Oncology. 42(4_suppl). 569–569. 1 indexed citations

Vlachou, Evangelia, Roy Elias, Noah M. Hahn, et al.. (2024). Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).. Journal of Clinical Oncology. 42(4_suppl). 570–570. 1 indexed citations

Baraban, Ezra, Roy Elias, Ming-Tseh Lin, et al.. (2024). High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset. Modern Pathology. 37(5). 100472–100472. 3 indexed citations

Rezaee, Michael E., Roy Elias, Pranjal Agrawal, et al.. (2024). Survival outcomes and molecular drivers of testicular cancer in hispanic men. Urologic Oncology Seminars and Original Investigations. 42(9). 293.e1–293.e7. 2 indexed citations

Alam, Ridwan, Michael E. Rezaee, Maximilian Pallauf, et al.. (2023). Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 41(11). 460.e1–460.e9. 3 indexed citations

Yin, Jianyi, Roy Elias, Lan Peng, et al.. (2022). Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(3). 260–269. 16 indexed citations

10.

Mulgaonkar, Aditi, Roy Elias, Layton Woolford, et al.. (2022). ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. Clinical Cancer Research. 28(22). 4907–4916. 10 indexed citations

11.

Zhou, Jin, Jeremy M. Simon, Chengheng Liao, et al.. (2022). An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Molecular Cell. 82(16). 3030–3044.e8. 33 indexed citations

12.

Elias, Roy, Alana Christie, Noelle S. Williams, et al.. (2021). Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. PubMed. 6(1). 69–79. 1 indexed citations

13.

Reig, Òscar, Akhilesh Mishra, Alana Christie, et al.. (2021). Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology. 81(6). 555–558. 9 indexed citations

14.

Beuselinck, Benoit, Nazlı Dizman, Katharine A. Collier, et al.. (2021). Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.. Journal of Clinical Oncology. 39(15_suppl). 4557–4557. 1 indexed citations

15.

Patel, Viral, Roy Elias, William Schwartzman, et al.. (2020). Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e001198–e001198. 24 indexed citations

16.

Singla, Nirmish, Roy Elias, Rashed Ghandour, et al.. (2019). Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 37(12). 924–931. 41 indexed citations

17.

Elias, Roy, Payal Kapur, Iván Pedrosa, & James Brugarolas. (2018). Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back. Clinical Genitourinary Cancer. 16(6). 485–488. 5 indexed citations

18.

Park, Wungki, Deukwoo Kwon, Amrita Desai, et al.. (2017). Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clinical Lung Cancer. 19(3). 280–288.e4. 45 indexed citations

19.

Park, Wungki, Amrita Desai, Fernando Regla Vargas, et al.. (2017). P3.02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Thoracic Oncology. 12(1). S1327–S1327. 1 indexed citations

20.

Bryant, Victoria, Roy Elias, Susan McCarthy, Timothy J. Yeatman, & Mark G. Alexandrow. (2015). Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil. Molecular Cancer Research. 13(9). 1296–1305. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact